Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of Malononitrilamides in Neuropathic Pain

a technology of malononitrilamide and neuropathic pain, which is applied in the field of malonitrilamides, can solve the problems of peripheral neuropathic pain, severe impairment of overall quality of life, and most devastating effects

Inactive Publication Date: 2013-08-22
ALGIAX PHARMA
View PDF1 Cites 52 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent and its related patent text describe a new group of compounds that can be used to treat neuropathic pain, a type of pain that is caused by damage to the natosynaptic nervous system. The compounds described in the patent can help to reduce or prevent this pain by blocking certain receptors in the body that are involved in its transmission. These compounds may be administered alone or in combination with other drugs to achieve better results. The patent also mentions the use of certain malononitrilamides and their derivatives as possible treatments for neuropathic pain. Overall, the patent presents a new tool for the treatment of a challenging and potentially debilitating condition.

Problems solved by technology

One of the most relevant pains is neuropathic pain which severely impairs the overall quality of life, and which is one of the most devastating forms of chronic pain.
Peripheral nerve injury or dysfunction can result in peripheral neuropathic pain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Malononitrilamides in Neuropathic Pain
  • Use of Malononitrilamides in Neuropathic Pain
  • Use of Malononitrilamides in Neuropathic Pain

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0138]Laflunimus (HR325) treatment to suppress the development of mechanical allodynia after severe spinal cord contusion injury in the rat.

[0139]Surgical Methods

[0140]Thirteen week-old female Lewis rats (Charles River, Sulzfeld Germany) were housed under a 12:12 h dark / light regime and allowed free access to water and food. After one week of habituation the animals underwent general anesthesia with a mixture of isoflurane and air (induction: 5% isoflurane, maintenance: 2.2% isofluorane). A Th10 laminectomy was performed without rupturing the dura and a severe contusive SCI (25 gcm NYU / MASCIS II impactor) {Gruner, 1992#3} was induced. After suturing muscle and skin, a subcutaneous (s.c.) injection of 5 ml of Ringers Lactate was given. Bladders were emptied manually 2 times a day until spontaneous voiding returned (usually within 1 week). The lesion severity was verified by the impact velocity and contusion depth of the impactor rod. Animals with an impact velocity error >5% were exc...

example 2

[0146]HR325 and FK778 treatment can both reverse central neuropathic pain induced by severe spinal cord contusion injury in the rat.

[0147]Surgical Methods

[0148]For surgical methods see example 1.

[0149]After injury, individual rats were randomly assigned into a treatment group. The following groups were used:

Group 1: SCI+vehicle (1.5% CMC in sterile water) by gavage for 7 days, from DPO 28 till DPO 35

Group 2: SCI+HR 325 (10 mg / kg / day) in vehicle by gavage for 7 days, from DPO 28 till DPO 35

Group 3: SCI+FK 778 (10 mg / kg / day) in vehicle by gavage for 7 day, from DPO 28 till DPO 35

[0150]Assessment of Mechanical Sensitivity:

[0151]For the assessment of mechanical sensitivity see example 1.

[0152]The Acetone Test:

[0153]A slightly modified method of De la Calle and colleagues (De la Calle et al., 2002) was used for the determination of the reactivity to a cold chemical stimulus. The rat was placed in acrylic cages on top of a wire mesh grid, which allowed access to the paws, and acetone was ...

example 3

[0159]HR325 treatment can reverse chronic central neuropathic pain three months after spinal cord contusion injury.

[0160]Surgical Methods

[0161]For surgical methods see example 1.

[0162]After injury, individual rats were randomly assigned into a treatment group. The following groups were used:

Group 1: SCI+vehicle (1.5% CMC in sterile water) by gavage for 7 days, from DPO 84 till DPO 91

Group 2: SCI+HR 325 (10 mg / kg / day) in vehicle by gavage for 7 days, from DPO 84 till DPO 91

[0163]Assessment of Mechanical Sensitivity:

[0164]For the assessment of mechanical sensitivity see example 1.

[0165]The Acetone Test:

[0166]For the assessment of mechanical sensitivity see example 2.

[0167]Results:

[0168]Mechanical Sensitivity

[0169]The mechanical sensitivity (indicated by the 50% threshold force for paw withdrawals) was determined by the Up-Down method using von Frey filaments. All rats were baseline tested before surgery and tested again on day 28 post surgery, because this is the first time point at w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
paw withdrawal thresholdaaaaaaaaaa
50% paw withdrawal thresholdaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

Provided herein are compounds and pharmaceutical compositions for use in the treatment of neuropathic pain and the neuropathic pain syndromes.

Description

FIELD OF THE DISCLOSURE[0001]The technology provided herein relates to the novel use of malononitrilamides and its derivatives in the treatment of neuropathic pain and neuropathic pain syndromes.BACKGROUND[0002]The treatment of pain conditions is of great importance in medicine. There is currently a world-wide need for additional pain therapy. The pressing requirement for a specific treatment of pain conditions is documented in the large number of scientific works that have appeared recently in the field of applied analgesics.[0003]Pain is defined by the International Association for the Study of Pain (IASP) as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”. Although pain is always subjective, its causes or syndromes can be classified. One of the most relevant pains is neuropathic pain which severely impairs the overall quality of life, and which is one of the most devastating forms of chronic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/164A61K31/42
CPCA61K31/275A61K31/167A61K31/42A61K31/164A61P25/04A61P25/06A61P29/00
Inventor HASSE, BIRGITKOOPMANS, GUIDO
Owner ALGIAX PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com